7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical phenotypes and heath-related quality of life of COPD patients in a rural setting in Malaysia – a cross-sectional study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The Spanish chronic obstructive pulmonary disease (COPD) guideline phenotypes patients according to the exacerbation frequency and COPD subtypes. In this study, we compared the patients’ health-related quality of life (HRQoL) according to their COPD phenotypes.

          Methods

          This was a cross-sectional study of COPD patients who attended the outpatient clinic of the Serian Divisional Hospital and Bau District Hospital from 23th January 2018 to 22th January 2019. The HRQoL was assessed using modified Medical Research Council (mMRC), COPD Assessment Test (CAT), and St George’s Respiratory Questionnaire for COPD (SGRQ-c).

          Results

          Of 185 patients, 108 (58.4%) were non-exacerbators (NON-AE), 51 (27.6%) were frequent exacerbators (AE), and the remaining 26 (14.1%) had asthma-COPD overlap (ACO). Of AE patients, 42 (82.4%) had chronic bronchitis and only 9 (17.6%) had emphysema. Of the 185 COPD patients, 65.9% had exposure to biomass fuel and 69.1% were ex- or current smokers.

          The scores of mMRC, CAT, and SGRQ-c were significantly different between COPD phenotypes ( p <  0.001). There were significantly more patients with mMRC 2–4 among AE (68.6%) ( p <  0.001), compared to those with ACO (38.5%) and NON-AE (16.7%). AE patients had significantly higher total CAT ( p = 0.003; p <  0.001) and SGRQ-c (both p <  0.001) scores than those with ACO and NON-AE. Patients with ACO had significantly higher total CAT and SGRQ-c (both p <  0.001) scores than those with NON-AE.

          AE patients had significantly higher score in each item of CAT and component of SGRQ-c compared to those with NON-AE (all p <  0.001), and ACO [( p = 0.003–0.016; p = < 0.001–0.005) except CAT 1, 2 and 7. ACO patients had significantly higher score in each item of CAT and component of SGRQ-c ( p = < 0.001–0.040; p <  0.001) except CAT 2 and activity components of SGRQ-c.

          Conclusions

          The HRQoL of COPD patients was significantly different across different COPD phenotypes. HRQoL was worst in AE, followed by ACO and NON-AE. This study supports phenotyping COPD patients based on their exacerbation frequency and COPD subtypes. The treatment of COPD should be personalised according to these two factors.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            How to Calculate Sample Size for Different Study Designs in Medical Research?

            Calculation of exact sample size is an important part of research design. It is very important to understand that different study design need different method of sample size calculation and one formula cannot be used in all designs. In this short review we tried to educate researcher regarding various method of sample size calculation available for different study designs. In this review sample size calculation for most frequently used study designs are mentioned. For genetic and microbiological studies readers are requested to read other sources.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Understanding the impact of symptoms on the burden of COPD

              Chronic obstructive pulmonary disease (COPD) imposes a substantial burden on individuals with the disease, which can include a range of symptoms (breathlessness, cough, sputum production, wheeze, chest tightness) of varying severities. We present an overview of the biomedical literature describing reported relationships between COPD symptoms and disease burden in terms of quality of life, health status, daily activities, physical activity, sleep, comorbid anxiety, and depression, as well as risk of exacerbations and disease prognosis. In addition, the substantial variability of COPD symptoms encountered (morning, daytime, and nighttime) is addressed and their implications for disease burden considered. The findings from this narrative review, which mainly focuses on real-world and observational studies, demonstrate the impact of COPD symptoms on the burden of disease and that improved recognition and understanding of their impact is central to alleviating this burden.
                Bookmark

                Author and article information

                Contributors
                cschai@unimas.my
                sumastika@gmail.com
                diananglehching@gmail.com
                kcgoh@unimas.my
                stanselm@unimas.my
                dr.muhd.amin@gmail.com
                aisyanatasya@gmail.com
                pramudita_1@hotmail.com
                yongkek@gmail.com
                liamck@ummc.edu.my
                Journal
                BMC Pulm Med
                BMC Pulm Med
                BMC Pulmonary Medicine
                BioMed Central (London )
                1471-2466
                29 September 2020
                29 September 2020
                2020
                : 20
                : 254
                Affiliations
                [1 ]GRID grid.412253.3, ISNI 0000 0000 9534 9846, Department of Medicine, Faculty of Medicine and Health Science, , University Malaysia Sarawak, ; Kota Samarahan, Sarawak Malaysia
                [2 ]GRID grid.412253.3, ISNI 0000 0000 9534 9846, Department of Nursing, Faculty of Medicine and Health Science, , University Malaysia Sarawak, ; Kota Samarahan, Sarawak Malaysia
                [3 ]GRID grid.412253.3, ISNI 0000 0000 9534 9846, Department of Community Medicine and Public Health, Faculty of Medicine and Health Science, , University Malaysia Sarawak, ; Kota Samarahan, Sarawak Malaysia
                [4 ]Department of Medicine, Faculty of Medicine, University Technology MARA, Sungai Buloh, Selangor Malaysia
                [5 ]GRID grid.10347.31, ISNI 0000 0001 2308 5949, Department of Medicine, Faculty of Medicine, , University of Malaya, ; Kuala Lumpur, Malaysia
                Author information
                http://orcid.org/0000-0002-4277-6152
                Article
                1295
                10.1186/s12890-020-01295-4
                7526228
                32993591
                58965218-00c6-4d06-8ab7-5052d6ed6b3d
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 10 June 2020
                : 16 September 2020
                Funding
                Funded by: Ministry of Higher Education, Malaysia
                Award ID: RAGS/1/2015/SKK02/UNIMAS/03/2 or FA052000-0708-0029
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Respiratory medicine
                chronic obstructive pulmonary disease,clinical phenotypes,health-related quality of life,exacerbators,asthma overlap

                Comments

                Comment on this article